Back to Stocks

ORIC

Oric Pharmaceuticals, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

ORIC Pharmaceuticals is transitioning from a broad discovery-stage entity into a focused, late-stage biopharma developer. The company has successfully consolidated its pipeline around two high-conviction assets: rinzimetostat for prostate cancer and enozertinib for lung cancer.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic clinical narrative, ORIC's financial trajectory reveals a deepening deficit and accelerating burn. The company reported a net loss of $35.8 million for the first quarter of 2026, contributing to an accumulated deficit of $728 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ORIC filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing highlights a company at a critical inflection point. ORIC has successfully de-risked its early-stage pipeline by prioritizing its most promising assets and securing the capital necessary to enter pivotal trials. The move to a Phase 3-ready profile is a significant value-inflection event that shifts the investment thesis from speculative discovery to clinical execution. However, the ultimate success of the company depends on its ability to translate Phase 1b signals into statistically significant Phase 3 outcomes while managing a high burn rate. Investors must weigh the impressive early efficacy and safety data against the reality of a crowded competitive field and the immense capital requirements of global registrational trials. The next 12 to 18 months will be decisive as the Himalayas-1 trial progresses and enozertinib data matures.

Selected Quarter

Core Takeaway

ORIC is shifting from a discovery-focused firm to a late-stage developer with a clear path to Phase 3 trials, backed by $419.7M in liquidity.

Investor Lens

The trade-off is between the high-conviction clinical data and the high probability of further dilution as Phase 3 expenses scale.

Watch Next

Initiation and early enrollment metrics for the Himalayas-1 global Phase 3 trial.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.13Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise
70%
bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss
60%
bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression
50%
bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise
70%
bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss
60%
bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression
50%
bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise
70%
bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss
60%
bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression
50%
bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise
70%
bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss
60%
bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression
50%
bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise
70%
bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss
60%
bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression
50%
bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise
70%
bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss
60%
bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression
50%
bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise
70%
bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss
60%
bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression
50%

Filing History

10-QMay 4, 2026
Expand Sequence

The Q1 2026 filing highlights a company at a critical inflection point. ORIC has successfully de-risked its early-stage pipeline by prioritizing its most promising assets and securing the capital necessary to enter pivotal trials. The move to a Phase 3-ready profile is a significant value-inflection event that shifts the investment thesis from speculative discovery to clinical execution. However, the ultimate success of the company depends on its ability to translate Phase 1b signals into statistically significant Phase 3 outcomes while managing a high burn rate. Investors must weigh the impressive early efficacy and safety data against the reality of a crowded competitive field and the immense capital requirements of global registrational trials. The next 12 to 18 months will be decisive as the Himalayas-1 trial progresses and enozertinib data matures.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.